Dendritic Cells and Cancer Immunity

Trends in Immunology

Volumn 37, Issue 12, 2016, Pages 855-865

  Gardner, Alycia ^a,b   Ruffell, Brian ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

antigen presentation; cancer; dendritic cells; immunotherapy; tumor microenvironment; vaccination

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

CANCER THERAPY; CELL ACTIVATION; CLINICAL FEATURE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; IN VIVO STUDY; NEOPLASM; NONHUMAN; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TRANSPLANTATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CROSS-PRIMING; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84994074775     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.09.006     Document Type: Review

References (100)

1. 1 Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
2. 2 Mildner, A., Jung, S., Development and function of dendritic cell subsets. Immunity 40 (2014), 642–656.
3. 3 Merad, M., et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31 (2013), 563–604.
4. 4 Guilliams, M., et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45 (2016), 669–684.
5. + dendritic cells in cytotoxic T cell immunity. Science 322 (2008), 1097–1100.
6. + dendritic cells. J. Exp. Med. 208 (2011), 2005–2016.
7. + dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44 (2016), 924–938.
8. 8 Sanchez-Paulete, A.R., et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6 (2015), 71–79.
9. 9 Segura, E., Amigorena, S., Cross-presentation in mouse and human dendritic cells. Adv. Immunol. 127 (2015), 1–31.
10. + pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J. Exp. Med. 208 (2011), 1789–1797.
11. 11 Headley, M.B., et al. Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature 531 (2016), 513–517.
12. + dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30 (2016), 324–336.
13. 13 Engelhardt, J.J., et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21 (2012), 402–417.
14. 14 Anderson, M.J., et al. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J. Immunol. 178 (2007), 1268–1276.
15. 15 Gerner, M.Y., et al. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J. Immunol. 181 (2008), 155–164.
16. + T cells. J. Immunol. 195 (2015), 3482–3489.
17. + T lymphocytes. Cancer Res. 70 (2010), 8368–8377.
18. + T cells during the effector phase. J. Exp. Med. 207 (2010), 2469–2477.
19. + T-cell immunity in patients with malignant tumor. Clin. Cancer Res. 19 (2013), 4508–4520.
20. + T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J. Immunol. 165 (2000), 6047–6055.
21. 21 Broz, M.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26 (2014), 638–652.
22. – dendritic cells in vivo. J. Exp. Med. 196 (2002), 817–827.
23. 23 Platzer, B., et al. IgE/FcɛRI-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses. Cell Rep. 10 (2015), 1487–1495.
24. 24 Desch, A.N., et al. Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction. Nat. Commun., 5, 2014, 4674.
25. 25 Ma, Y., et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38 (2013), 729–741.
26. 26 Jakubzick, C., et al. Optimization of methods to study pulmonary dendritic cell migration reveals distinct capacities of DC subsets to acquire soluble versus particulate antigen. J. Immunol. Methods 337 (2008), 121–131.
27. 27 Zong, J., et al. Tumor-derived factors modulating dendritic cell function. Cancer Immunol. Immunother. 65 (2016), 821–833.
28. + T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26 (2014), 623–637.
29. 29 Spranger, S., et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
30. 30 Mellman, I., Steinman, R.M., Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001), 255–258.
31. 31 Zelenay, S., Reis e Sousa, C., Adaptive immunity after cell death. Trends Immunol. 34 (2013), 329–335.
32. 32 Kroemer, G., et al. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31 (2013), 51–72.
33. 33 Müller, T., et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy 65 (2010), 1545–1553.
34. 34 Ghiringhelli, F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15 (2009), 1170–1178.
35. 35 Idzko, M., et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat. Med. 13 (2007), 913–919.
36. 36 Obeid, M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 (2007), 54–61.
37. 37 Obeid, M., et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14 (2007), 1848–1850.
38. 38 Apetoh, L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007), 1050–1059.
39. 39 Messmer, D., et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173 (2004), 307–313.
40. 40 Schiraldi, M., et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209 (2012), 551–563.
41. 41 Pfirschke, C., et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44 (2016), 343–354.
42. 42 Chiba, S., et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13 (2012), 832–842.
43. 43 Woo, S.R., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842.
44. 44 Deng, L., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41 (2014), 843–852.
45. 45 Fuertes, M.B., et al. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34 (2013), 67–73.
46. 46 Diamond, M.S., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003.
47. 47 Corrales, L., et al. The host STING pathway at the interface of cancer and immunity. J. Clin. Invest. 126 (2016), 2404–2411.
48. 48 Pasparakis, M., Vandenabeele, P., Necroptosis and its role in inflammation. Nature 517 (2015), 311–320.
49. + T cells. Science 350 (2015), 328–334.
50. 50 Aaes, T.L., et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 15 (2016), 274–287.
51. 51 Rizvi, N.A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
52. 52 Van Allen, E.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
53. 53 Le, D.T., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
54. 54 DuPage, M., et al. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482 (2012), 405–409.
55. 55 Scarlett, U.K., et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209 (2012), 495–506.
56. 56 Roland, C.L., et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One, 4, 2009, e7669.
57. 57 Tang, M., et al. Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep. 13 (2015), 2851–2864.
58. 58 Doedens, A.L., et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 70 (2010), 7465–7475.
59. 59 Colegio, O.R., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563.
60. + dendritic cell subset that promotes the Th17 response. Immun. Inflamm. Dis. 3 (2015), 360–373.
61. 61 Gottfried, E., et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107 (2006), 2013–2021.
62. 62 O'Neill, L.A., Pearce, E.J., Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 213 (2016), 15–23.
63. 63 Cubillos-Ruiz, J.R., et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161 (2015), 1527–1538.
64. 64 Natsuaki, Y., et al. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat. Immunol. 15 (2014), 1064–1069.
65. 65 Iijima, N., Iwasaki, A., T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science 346 (2014), 93–98.
66. 66 Pitzalis, C., et al. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14 (2014), 447–462.
67. 67 Dieu-Nosjean, M.C., et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271 (2016), 260–275.
68. 68 Thompson, E.D., et al. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 207 (2010), 1791–1804.
69. 69 Joshi, N.S., et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43 (2015), 579–590.
70. 70 Schrama, D., et al. Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue. Cancer Immunol. Immunother. 57 (2008), 85–95.
71. 71 Yu, P., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5 (2004), 141–149.
72. 72 Kirk, C.J., et al. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 61 (2001), 8794–8802.
73. 73 Palucka, K., Banchereau, J., Dendritic-cell-based therapeutic cancer vaccines. Immunity 39 (2013), 38–48.
74. 74 Fu, J., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med., 7, 2015, 283ra52.
75. 75 Russell, S.J., et al. Oncolytic virotherapy. Nat Biotechnol. 30 (2012), 658–670.
76. 76 Kantoff, P.W., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363 (2010), 411–422.
77. 77 Burch, P.A., et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6 (2000), 2175–2182.
78. 78 Carreno, B.M., et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J. Clin. Invest. 123 (2013), 3383–3394.
79. 79 Carreno, B.M., et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (2015), 803–808.
80. 80 Kleindienst, P., Brocker, T., Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J. Immunol. 170 (2003), 2817–2823.
81. + T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One, 5, 2010, e11144.
82. + T cells to dendritic cell-based vaccines. PLoS One, 6, 2011, e17657.
83. 83 Mitchell, D.A., et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519 (2015), 366–369.
84. 84 Le, D.T., et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33 (2015), 1325–1333.
85. 85 Kranz, L.M., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534 (2016), 396–401.
86. + T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167 (2001), 5247–5253.
87. 87 Heckelsmiller, K., et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169 (2002), 3892–3899.
88. 88 Ohkuri, T., et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol. Res. 2 (2014), 1199–1208.
89. 89 Vicari, A.P., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196 (2002), 541–549.
90. 90 Swiecki, M., Colonna, M., The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 15 (2015), 471–485.
91. 91 Villadangos, J.A., Young, L., Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 29 (2008), 352–361.
92. + T-regulatory cells. Cancer Res. 72 (2012), 5240–5249.
93. 93 Treilleux, I., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10 (2004), 7466–7474.
94. 94 Le Mercier, I., et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 73 (2013), 4629–4640.
95. 95 Leon, B., Ardavin, C., Monocyte-derived dendritic cells in innate and adaptive immunity. Immunol. Cell Biol. 86 (2008), 320–324.
96. 96 Domínguez, P.M., Ardavín, C., Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 234 (2010), 90–104.
97. 97 Tamoutounour, S., et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity 39 (2013), 925–938.
98. + dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity 38 (2013), 322–335.
99. 99 Jakubzick, C., et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 39 (2013), 599–610.
100. 100 Marigo, I., et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 30 (2016), 377–390.